CD226, also known as DNAM1 (DNAX accessory molecule-1), is broadly expressed on T cells, natural killer (NK) cells, platelets, monocytes, and a subset of B cells, and it is also identified as a crucial co-activating receptor to restrain CD8+T-mediated anti-tumor response (13). The gene discussed is CD8A; the disease is neoplasm.